OliX PharmaceuticalsInc Cash Flow-to-Debt Ratio
OliX PharmaceuticalsInc cash flow-to-debt ratio. OliX PharmaceuticalsInc (226950) has a Cash Flow-to-Debt Ratio of -0.42x as of June 2026, meaning its operating cash flow of ₩-15.43 Billion could theoretically repay 0% of its total liabilities (₩36.64 Billion) in one year. Check OliX PharmaceuticalsInc (226950) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of OliX PharmaceuticalsInc (2016–2025)
Cash flow-to-debt ratio of OliX PharmaceuticalsInc from 2016 to 2025. Historical debt coverage capacity for OliX PharmaceuticalsInc across 10 annual periods. Check how aggressively does OliX PharmaceuticalsInc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
OliX PharmaceuticalsInc Cash Flow-to-Debt Ratio by Year (2016–2025)
OliX PharmaceuticalsInc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for OliX PharmaceuticalsInc. For the full cash flow conversion analysis, see cash efficiency ratio of OliX PharmaceuticalsInc.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | ₩-15.90 Billion | ₩45.29 Billion | ▲ +33.1% |
| 2024 | -0.53x | ₩-28.04 Billion | ₩53.40 Billion | ▼ -30.2% |
| 2023 | -0.40x | ₩-21.17 Billion | ₩52.49 Billion | ▲ +12.3% |
| 2022 | -0.46x | ₩-30.68 Billion | ₩66.74 Billion | ▼ -64.4% |
| 2021 | -0.28x | ₩-19.05 Billion | ₩68.15 Billion | ▼ -147.6% |
| 2020 | -0.11x | ₩-3.76 Billion | ₩33.29 Billion | ▲ +96.4% |
| 2019 | -3.15x | ₩-10.73 Billion | ₩3.41 Billion | ▲ +73.7% |
| 2018 | -11.96x | ₩-8.36 Billion | ₩698.94 Million | ▼ -640.5% |
| 2017 | -1.62x | ₩-4.79 Billion | ₩2.96 Billion | ▼ -21.4% |
| 2016 | -1.33x | ₩-3.45 Billion | ₩2.59 Billion | — |